+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Epidermolysis Bullosa Therapeutics Market 2019-2023 - Product Image

Global Epidermolysis Bullosa Therapeutics Market 2019-2023

  • ID: 4749719
  • Report
  • January 2019
  • Region: Global
  • 128 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Amryt Pharma
  • Fresenius
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • MORE
Despite the significant research activities undertaken over the past several decades, a promising treatment with very few side effects is not yet developed for the treatment of epidermolysis bullosa. Hence, various government and private organizations are releasing funds to advance the research on the development of promising therapeutics that can demonstrate better safety and efficacy than the available medications for the treatment of epidermolysis bullosa. The funding for the research on epidermolysis bullosa in Europe is also increasing. Such funding and financial supports are helpful for the development of novel therapeutic drugs for the treatment of epidermolysis bullosa. The analysts have predicted that the epidermolysis bullosa therapeutics market will register a CAGR of almost 5% by 2023.

Market Overview

Rising awareness about epidermolysis bullosa

Epidermolysis bullosa is a group of inherited diseases in which the skin becomes very brittle and forms acute blisters after a minor injury or gentle friction. Therefore, to avoid the delay in the diagnosis and the unawareness of the treatment options, several government and non-government organizations are conducting various awareness programs.

Lack of approved therapeutics

The unavailability of approved therapeutics for the treatment of epidermolysis bullosa is expected to hamper the growth of the epidermolysis bullosa therapeutics market over the forecast period.

For the detailed list of factors that will drive and challenge the growth of the epidermolysis bullosa therapeutics market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Amryt Pharma
  • Fresenius
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Antibiotics - Market size and forecast 2018-2023
  • Analgesics - Market size and forecast 2018-2023
  • Other therapeutics - Market size and forecast 2018-2023
  • Market opportunity by product
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 12: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amryt Pharma
  • Fresenius
  • Johnson & Johnson
  • Novartis
  • Pfizer
PART 13: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Years in consideration
Exhibit 02: Global rare diseases therapeutics market
Exhibit 03: Segments of global rare diseases therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Antibiotics - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Antibiotics - Year-over-year growth 2019-2023 (%)
Exhibit 21: Analgesics - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Analgesics - Year-over-year growth 2019-2023 (%)
Exhibit 23: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Other therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Top 3 countries in North America
Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 34: Top 3 countries in Europe
Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Asia
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in ROW
Exhibit 41: Key leading countries
Exhibit 42: Market opportunity
Exhibit 43: Decision framework
Exhibit 44: Recent therapeutics that have received orphan drug designation from the US FDA
Exhibit 45: Impact of drivers and challenges
Exhibit 46: Early phase developmental therapeutics for the treatment of epidermolysis bullosa
Exhibit 47: Vendor landscape
Exhibit 48: Landscape disruption
Exhibit 49: Vendors covered
Exhibit 50: Vendor classification
Exhibit 51: Market positioning of vendors
Exhibit 52: Amryt Pharma - Vendor overview
Exhibit 53: Amryt Pharma - Business segments
Exhibit 54: Amryt Pharma - Organizational developments
Exhibit 55: Amryt Pharma - Geographic focus
Exhibit 56: Amryt Pharma - Segment focus
Exhibit 57: Amryt Pharma - Key offerings
Exhibit 58: Amryt Pharma - Key customers
Exhibit 59: Fresenius - Vendor overview
Exhibit 60: Fresenius - Business segments
Exhibit 61: Fresenius - Organizational developments
Exhibit 62: Fresenius - Geographic focus
Exhibit 63: Fresenius - Segment focus
Exhibit 64: Fresenius - Key offerings
Exhibit 65: Fresenius - Key customers
Exhibit 66: Johnson & Johnson - Vendor overview
Exhibit 67: Johnson & Johnson - Business segments
Exhibit 68: Johnson & Johnson - Organizational developments
Exhibit 69: Johnson & Johnson - Geographic focus
Exhibit 70: Johnson & Johnson - Segment focus
Exhibit 71: Johnson & Johnson - Key offerings
Exhibit 72: Johnson & Johnson - Key customers
Exhibit 73: Novartis - Vendor overview
Exhibit 74: Novartis - Business segments
Exhibit 75: Novartis - Organizational developments
Exhibit 76: Novartis - Geographic focus
Exhibit 77: Novartis - Segment focus
Exhibit 78: Novartis - Key offerings
Exhibit 79: Novartis - Key customers
Exhibit 80: Pfizer - Vendor overview
Exhibit 81: Pfizer - Business segments
Exhibit 82: Pfizer - Organizational developments
Exhibit 83: Pfizer - Geographic focus
Exhibit 84: Pfizer - Segment focus
Exhibit 85: Pfizer - Key offerings
Exhibit 86: Pfizer - Key customers
Exhibit 87: Validation techniques employed for market sizing
Exhibit 88: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Amryt Pharma
  • Fresenius
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • MORE
Global Epidermolysis Bullosa Therapeutics Market 2019-2023

The analyst recognizes the following companies as the key players in the global epidermolysis bullosa therapeutics market: Amryt Pharma, Fresenius, Johnson & Johnson, Novartis, Pfizer.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advances of regenerative medicines in the clinical phases are expected to fuel the growth of the market.”

According to the report, one of the major drivers for this market is the special regulatory designations.

Further, the report states that one of the major factors hindering the growth of this market is the antibiotics resistance and side effects associated with symptomatic treatment.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Amryt Pharma
  • Fresenius
  • Johnson & Johnson
  • Novartis
  • Pfizer
Note: Product cover images may vary from those shown
Adroll
adroll